Premium
From pre‐clinical data to the clinics: identification of circulating inflammatory mediators as potential biomarkers for heart failure (1073.6)
Author(s) -
Altara Raffaele
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1073.6
Subject(s) - medicine , heart failure , biomarker , inflammation , cohort , biomarker discovery , disease , sample size determination , myocardial ischemia , inflammatory response , cardiology , ischemia , biology , proteomics , biochemistry , statistics , mathematics , gene
Inflammatory mediators (IMs) play a pivotal role during cardiac remodeling. In our study we focused on circulating IMs which might be used as biomarkers. In rodents with cardiac hypertrophy and permanent myocardial ischemia we showed a circulating inflammatory profile with a common increase of 4 IMs in the onset of heart failure (HF). To translate this finding to human HF, we established the baseline values of these IMs in healthy people. Thirty healthy volunteers were selected with no known inflammatory condition. Via a membrane‐based assay, we observed no consistent differences for ~40 inflammatory analytes among gender, sample type and time of collection. Thus, we proceeded to determine the circulating IMs in an age‐matched cohort of 30 HF patients. Interestingly, two of the four IMs from our animal models had higher concentrations in HF patients when compared to healthy controls. Besides, these IMs have never been investigated in this setting before. Furthermore, a principal component analysis of the two groups (controls + HF patients) illustrated that one of the IMs was optimally separating the two groups on the base of component 1. In conclusion, the two IMs discovered in pre‐clinics are upregulated in HF patients. Although this first set of results originates from a relatively small sample size, it is particularly encouraging that they might be biomarker candidates for prognostics and diagnostics of HF. Grant Funding Source : Supported by the CTMM and the Dutch Heart Foundation (TRIUMPH).